Takeda gets Japanese rights to Exelixis' cabozantinib

Exelixis Inc. (NASDAQ:EXEL) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive, Japanese rights to cancer drug cabozantinib. The drug

Read the full 186 word article

User Sign In